GuidelinesHypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
Section snippets
Methods
The Hypertension Canada Guidelines Committee (HCGC) is a multidisciplinary panel of content as well as methodological experts comprised of a Chair, a Central Review Committee with a designated Chair, and 15 subgroups. Each subgroup addresses a distinct content area in hypertension (see Supplemental Appendix S1 for the current membership list). All HCGC members are volunteers.
Systematic literature searches to August 2016 were performed by a librarian from the Cochrane Collaboration in
I. Accurate measurement of BP
Background. There are no changes to these guidelines for 2017.
Guidelines Health care professionals who have been specifically trained to measure BP accurately should assess BP in all adult patients at all appropriate visits to determine cardiovascular risk and monitor antihypertensive treatment (Grade D). Use of standardized measurement techniques and validated equipment for all methods (automated office BP [AOBP], non-AOBP, home BP monitoring, and ambulatory BP monitoring) is recommended (Grade D; see
Hypertension Canada's 2017 Guidelines: Prevention and Treatment of Hypertension
Please note, hereafter, all treatment thresholds and targets refer to non-AOBP measurements performed in-office (see Supplemental Table S2, section on Recommended Technique for Automated Office Blood Pressure [AOBP]), because most of the supporting evidence is derived from studies using this method of BP measurement. Please refer to the section on Hypertension Canada's 2017 Guidelines: Diagnosis and Assessment of Hypertension, section II, Criteria for Diagnosis of Hypertension and Guidelines
Implementation
Implementation and dissemination of the guidelines is a priority for Hypertension Canada. We use many strategies to reach out to a variety of providers who care for patients with hypertension. Our efforts include knowledge exchange forums, targeted educational materials for primary care providers and patients, “Train the Trainer” teaching sessions, as well as slide kits and summary documents, which are freely available online in French and English (www.hypertension.ca). Hypertension Canada
Acknowledgements
We thank Ms Susan Carter for providing technical assistance with the manuscript and administrative support.
Funding Sources
Activities of the HCGC are supported by Hypertension Canada. The members of the HCGC are unpaid volunteers who contribute their time and expertise to the annual development and dissemination of the Hypertension Canada guidelines. To maintain professional credibility of the content, the process for the development of the guidelines is fully independent and free from external influence. External partners assist with the dissemination of the approved guidelines.
Disclosures
Please see Supplemental Appendix S2 for a complete list of disclosures.
References (88)
- et al.
Epidemiology of hypertension in Canada: an update
Can J Cardiol
(2016) - et al.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Lancet
(2004) - et al.
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Lancet
(2012) - et al.
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part I–blood pressure measurement, diagnosis and assessment of risk
Can J Cardiol
(2006) - et al.
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy
Can J Cardiol
(2006) - et al.
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk
Can J Cardiol
(2007) - et al.
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy
Can J Cardiol
(2007) - et al.
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis and assessment of risk
Can J Cardiol
(2008) - et al.
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy
Can J Cardiol
(2008) - et al.
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1–blood pressure measurement, diagnosis and assessment of risk
Can J Cardiol
(2009)
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2–therapy
Can J Cardiol
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk
Can J Cardiol
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy
Can J Cardiol
The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy
Can J Cardiol
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension
Can J Cardiol
The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension
Can J Cardiol
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension
Can J Cardiol
Hypertension Canada’s 2016 Canadian Hypertension Education Program Guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension
Can J Cardiol
The Canadian Hypertension Education Program–a unique Canadian initiative
Can J Cardiol
Fibromuscular dysplasia in living renal donors: still a challenge to computed tomographic angiography
Eur J Radiol
Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension trial. DASH Collaborative Research Group
J Am Diet Assoc
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
Lancet
Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring
J Am Coll Cardiol
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials
Am J Med
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
Lancet
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
Lancet
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Lancet
The long-term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia
J Vasc Surg
Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system
Mayo Clin Proc
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Lancet
Blood pressure as a cardiovascular risk factor: prevention and treatment
JAMA
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries
JAMA
1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension
CMAJ
Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades
CMAJ
The 2000 Canadian recommendations for the management of hypertension: part two–diagnosis and assessment of people with high blood pressure
Can J Cardiol
The 2001 Canadian recommendations for the management of hypertension: part one–assessment for diagnosis, cardiovascular risk, causes and lifestyle modification
Can J Cardiol
The 2001 Canadian recommendations for the management of hypertension: part two–therapy
Can J Cardiol
The Canadian recommendations for the management of hypertension
Can Pharm J
The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: part i–blood pressure measurement, diagnosis and assessment of risk
Can J Cardiol
The 2004 Canadian recommendations for the management of hypertension: part II–therapy
Can J Cardiol
The 2004 Canadian recommendations for the management of hypertension: part III–lifestyle modifications to prevent and control hypertension
Can J Cardiol
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk
Can J Cardiol
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy
Can J Cardiol
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy
Can J Cardiol
Cited by (244)
Defining rural spaces within pharmacy practice research: Current practice and implications
2023, Journal of the American Pharmacists AssociationPopulation-Based Recalibration of the Framingham Risk Score and Pooled Cohort Equations
2022, Journal of the American College of CardiologyHAPI Fit: An Exercise Intervention to Improve Peak Aerobic Capacity in Young Adults Born Very Preterm
2024, Medicine and Science in Sports and Exercise
See page 573 for disclosure information.